Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 5
1968 2
1969 1
1970 1
1971 3
1972 2
1973 2
1974 1
1975 1
1976 2
1977 3
1978 4
1979 4
1980 3
1981 3
1982 4
1983 7
1984 3
1985 6
1986 5
1987 5
1988 4
1989 3
1990 5
1991 12
1992 7
1993 11
1994 10
1995 9
1996 16
1997 6
1998 9
1999 5
2000 3
2001 6
2002 3
2003 3
2004 4
2005 2
2007 1
2008 1
2009 2
2010 3
2011 1
2012 2
2013 5
2014 4
2015 1
2016 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
[Targeted therapy of polycytemia vera patients].
Shikhbabaeva DI, Shuvaev VA, Martynkevich IS, Zyuzgin IS, Abdulkadyrov KM. Shikhbabaeva DI, et al. Among authors: abdulkadyrov km. Vopr Onkol. 2016;62(4):386-93. Vopr Onkol. 2016. PMID: 30474944 Review. Russian.
Sotatercept in patients with osteolytic lesions of multiple myeloma.
Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E. Abdulkadyrov KM, et al. Br J Haematol. 2014 Jun;165(6):814-23. doi: 10.1111/bjh.12835. Epub 2014 Mar 21. Br J Haematol. 2014. PMID: 24650009 Free PMC article. Clinical Trial.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. San Miguel JF, et al. Among authors: abdulkadyrov km. N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479. N Engl J Med. 2008. PMID: 18753647 Free article. Clinical Trial.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ; FIGHT-AML-301 Investigators. Harousseau JL, et al. Blood. 2009 Aug 6;114(6):1166-73. doi: 10.1182/blood-2009-01-198093. Epub 2009 May 21. Blood. 2009. PMID: 19470696 Free article. Clinical Trial.
[Chronic eosinophilic myeloleukemia].
Abdulkadyrov KM, Rugal' VI. Abdulkadyrov KM, et al. Vrach Delo. 1983 May;(5):52-4. Vrach Delo. 1983. PMID: 6576507 Russian. No abstract available.
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF. Mateos MV, et al. Among authors: abdulkadyrov km. J Clin Oncol. 2010 May 1;28(13):2259-66. doi: 10.1200/JCO.2009.26.0638. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368561 Free article. Clinical Trial.
[The etiology of aplastic anemia].
Abdulkadyrov KM, Bessmel'tsev SS, Shilova ER. Abdulkadyrov KM, et al. Lik Sprava. 1995 Sep-Dec;(9-12):16-21. Lik Sprava. 1995. PMID: 8983764 Review. Russian. No abstract available.
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG. San Miguel JF, et al. Among authors: abdulkadyrov km. J Clin Oncol. 2013 Feb 1;31(4):448-55. doi: 10.1200/JCO.2012.41.6180. Epub 2012 Dec 10. J Clin Oncol. 2013. PMID: 23233713 Free article. Clinical Trial.
208 results